Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo-Reference-Cited by-同舟云学术

Lack of CYP3A4 protein induction despite mRNA induction in primary hepatocytes exposed to rifabutin as a possible explanation for its low interaction risk in vivo

Published:2024-05-07 Issue:8 Volume:98 Page:2541-2556
ISSN:0340-5761
Container-title:Archives of Toxicology
language:en
Short-container-title:Arch Toxicol

Author:

Nilles Julie,Theile Dirk,Weiss Johanna,Haefeli Walter E.,Ruez Stephanie^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s00204-024-03763-w.pdf

Reference39 articles.

1. Baciewicz AM, Chrisman CR, Finch CK, Self TH (2008) Update on rifampin and rifabutin drug interactions. Am J Med Sci 335:126–136. https://doi.org/10.1097/MAJ.0b013e31814a586a

2. Barluenga J, Aznar F, García A, Cabal M, Palacios JJ, Menéndez M (2006) New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg Med Chem Lett 16:5717–5722. https://doi.org/10.1016/j.bmcl.2006.08.090

3. Chen Y, Ferguson SS, Negishi M, Goldstein JA (2003) Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol Pharmacol 64:316–324. https://doi.org/10.1124/mol.64.2.316

4. Chen Y, Ferguson SS, Negishi M, Goldstein JA (2004) Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 308:495–501. https://doi.org/10.1124/jpet.103.058818

5. Committee for Medicinal Products for Human Use, European Medicines Agency, Guideline on the investigation of drug interactions, 2012, CPMP/EWP/560/95/Rev. 1 Corr. 2**. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf (Accessed on 5 February 2024)